Clinical Trial Update: Efficacy, Immunogenicity and Safety of S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 6 Months to 5 Years [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update evaluating efficacy, immunogenicity, and safety of a bivalent Shigella vaccine in children aged 6 months to 5 years.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dysentery
• Shigellosis

Drugs mentioned

• S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine (S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine)

Snippet

Sponsor: Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | Conditions: Dysentery, Shigellosis | Phase 3 | Status: UNKNOWN